Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution

The article presents updated information on the frequency of use of non-recommended low dosing of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). It gives substantiation of the urgency of the issue of providing the maximum efficiency of the use of anticoagulants in clini...

Full description

Bibliographic Details
Main Authors: S. R. Gilyarevskiy, N. G. Bendeliani, M. V. Golshmid, I. M. Kuzmina
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-10-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/6428
_version_ 1797841716671152128
author S. R. Gilyarevskiy
N. G. Bendeliani
M. V. Golshmid
I. M. Kuzmina
author_facet S. R. Gilyarevskiy
N. G. Bendeliani
M. V. Golshmid
I. M. Kuzmina
author_sort S. R. Gilyarevskiy
collection DOAJ
description The article presents updated information on the frequency of use of non-recommended low dosing of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). It gives substantiation of the urgency of the issue of providing the maximum efficiency of the use of anticoagulants in clinical practice, taking into account the high prevalence of atrial fibrillation and the pharmacological characteristics of the most commonly used drugs. The effects of such an unreasonable reduction in anticoagulant doses in elderly and senile patients are discussed. The results of recent observational studies that assessed the relationship between the use of direct oral anticoagulants and the risk of adverse clinical outcomes are presented. The data on the relationship between the use of unreasonably low dosing of anticoagulants in patients with atrial fibrillation, which were recently obtained during the implementation of the GARFIELD-AF registry, are discussed. The data on a rather high variability of concentrations of direct oral anticoagulants are presented. The frequency of using apixaban in an unreasonably reduced dose, as well as the effects of using non-recommended doses of apixaban hold a specific place in the article. The unreasonableness of attempts to further reduce the risk of bleeding due to unreasonable reduction of apixaban dosing is emphasized, taking into account the stable data on the high safety of recommended dosing of apixaban, as well as the possible decrease in the effect if the dose reduction is not recommended. The data on the criteria for dose reduction, which are adopted in different countries, are presented. The proposed terms to designate different doses of direct oral anticoagulants, depending on their study in the course of large, randomized trials are discussed.
first_indexed 2024-04-09T16:36:24Z
format Article
id doaj.art-b2435dbd898c4469ab5f530582ce6893
institution Directory Open Access Journal
issn 2079-701X
2658-5790
language Russian
last_indexed 2024-04-09T16:36:24Z
publishDate 2021-10-01
publisher Remedium Group LLC
record_format Article
series Медицинский совет
spelling doaj.art-b2435dbd898c4469ab5f530582ce68932023-04-23T06:56:53ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-10-01014687610.21518/2079-701X-2021-14-68-765799Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solutionS. R. Gilyarevskiy0N. G. Bendeliani1M. V. Golshmid2I. M. Kuzmina3Russian Medical Academy of Continuing Postgraduate EducationInstitute for Coronary and Vascular Surgery of A.N. Bakulev National Medical Research Center of Cardiovascular SurgeryRussian Medical Academy of Continuing Postgraduate EducationSklifosovskiy Research Institute for Emergency MedicineThe article presents updated information on the frequency of use of non-recommended low dosing of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). It gives substantiation of the urgency of the issue of providing the maximum efficiency of the use of anticoagulants in clinical practice, taking into account the high prevalence of atrial fibrillation and the pharmacological characteristics of the most commonly used drugs. The effects of such an unreasonable reduction in anticoagulant doses in elderly and senile patients are discussed. The results of recent observational studies that assessed the relationship between the use of direct oral anticoagulants and the risk of adverse clinical outcomes are presented. The data on the relationship between the use of unreasonably low dosing of anticoagulants in patients with atrial fibrillation, which were recently obtained during the implementation of the GARFIELD-AF registry, are discussed. The data on a rather high variability of concentrations of direct oral anticoagulants are presented. The frequency of using apixaban in an unreasonably reduced dose, as well as the effects of using non-recommended doses of apixaban hold a specific place in the article. The unreasonableness of attempts to further reduce the risk of bleeding due to unreasonable reduction of apixaban dosing is emphasized, taking into account the stable data on the high safety of recommended dosing of apixaban, as well as the possible decrease in the effect if the dose reduction is not recommended. The data on the criteria for dose reduction, which are adopted in different countries, are presented. The proposed terms to designate different doses of direct oral anticoagulants, depending on their study in the course of large, randomized trials are discussed.https://www.med-sovet.pro/jour/article/view/6428direct oral anticoagulantsnon-recommended low dosesatrial fibrillationapixabanrivaroxabandabigatran
spellingShingle S. R. Gilyarevskiy
N. G. Bendeliani
M. V. Golshmid
I. M. Kuzmina
Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution
Медицинский совет
direct oral anticoagulants
non-recommended low doses
atrial fibrillation
apixaban
rivaroxaban
dabigatran
title Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution
title_full Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution
title_fullStr Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution
title_full_unstemmed Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution
title_short Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution
title_sort systematic errors in the choice of dose level of direct oral anticoagulants urgency of an issue and approaches to its solution
topic direct oral anticoagulants
non-recommended low doses
atrial fibrillation
apixaban
rivaroxaban
dabigatran
url https://www.med-sovet.pro/jour/article/view/6428
work_keys_str_mv AT srgilyarevskiy systematicerrorsinthechoiceofdoselevelofdirectoralanticoagulantsurgencyofanissueandapproachestoitssolution
AT ngbendeliani systematicerrorsinthechoiceofdoselevelofdirectoralanticoagulantsurgencyofanissueandapproachestoitssolution
AT mvgolshmid systematicerrorsinthechoiceofdoselevelofdirectoralanticoagulantsurgencyofanissueandapproachestoitssolution
AT imkuzmina systematicerrorsinthechoiceofdoselevelofdirectoralanticoagulantsurgencyofanissueandapproachestoitssolution